Drug updated on 3/28/2024
| Dosage Form | Tablet (oral; 200 mg) |
| Drug Class | Methyltransferase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
- Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies.
- Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.
Summary
- Tazemetostat (Tazverik) is used for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection, as well as adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation.
- Two systematic reviews/meta-analyses were reviewed that provide information on the use of tazemetostat in cancer therapy.
- The first study highlights that tazemetostat, a histone methyltransferase inhibitor, has shown considerable anti-tumor effects particularly in treating hematological cancers such as follicular lymphoma.
- According to this review, adverse effects presented after using these medicines did not show a high level of risk for the patient which suggests its relative safety compared to other treatments.
- The second review provides an indirect comparison between tazmetostat and phosphoinositide 3-kinase inhibitors idelalisib, copanlisib, umbralisib and duvelisib in third-line or later treatment of relapsed/refractory follicular lymphoma.
- This analysis found that while achieving similar efficacy outcomes to these drugs; tazmetostat was associated with lower relative risk for serious treatment-emergent adverse events leading to dose reduction, drug discontinuation or interruption indicating it may be safer option among available therapies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Tazverik (tazemetostat) Prescribing Information. | 2020 | Epizyme Inc., Cambridge, MA |